ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
1.210
-0.020 (-1.63%)
Nov 20, 2024, 4:00 PM EST - Market closed
ALX Oncology Holdings Employees
ALX Oncology Holdings had 72 employees as of December 31, 2023. The number of employees increased by 14 or 24.14% compared to the previous year.
Employees
72
Change (1Y)
14
Growth (1Y)
24.14%
Revenue / Employee
n/a
Profits / Employee
-$2,099,431
Market Cap
63.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 72 | 14 | 24.14% |
| Dec 31, 2022 | 58 | 15 | 34.88% |
| Dec 31, 2021 | 43 | 20 | 86.96% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 120 |
| AlloVir | 112 |
| electroCore | 68 |
| InspireMD | 66 |
| Cue Biopharma | 53 |
| Forian | 37 |
| HeartBeam | 15 |
ALXO News
- 6 days ago - ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer - GlobeNewsWire
- 13 days ago - ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 19 days ago - ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 - GlobeNewsWire
- 2 months ago - ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations - Seeking Alpha
- 3 months ago - ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors - GlobeNewsWire
- 4 months ago - ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer - GlobeNewsWire
- 4 months ago - ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer - GlobeNewsWire
- 5 months ago - ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation - Seeking Alpha